CagriSema's Potential to Improve Blood Sugar and Weight in Type 2 Diabetes

Type 2 Diabetes is a progressive metabolic disorder characterized by high blood sugar, often requiring complex treatment regimens. While semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog) are individually effective for glycemic control and weight loss, their combined potential in patients already on basal insulin remains under investigation. This Phase 3 study aims to determine the efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) as an add-on therapy for Type 2 Diabetes patients treated with basal insulin, addressing if the combination offers superior benefits.

As this Phase 3 clinical trial is still ongoing with a projected completion date of October 2025, specific efficacy and safety data for CagriSema compared to placebo are not yet published. The study has completed its enrollment of 274 participants. Primary endpoints are expected to include changes in HbA1c (a measure of average blood sugar over 2-3 months) and body weight from baseline. Researchers will be evaluating the dose-dependent effects of CagriSema at 2.4 mg/2.4 mg and 1.0 mg/1.0 mg on these key metabolic parameters. > The most important finding will be whether CagriSema demonstrates a statistically significant and clinically meaningful reduction in HbA1c and body weight compared to placebo in this specific patient population. Further analysis will compare the safety profiles, including adverse events, across the treatment groups.